{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:23:21Z","timestamp":1768281801137,"version":"3.49.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"34","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/open-government-licence\/version\/3\/"}],"funder":[{"name":"European Union\u2019s Seventh Framework","award":["602012"],"award-info":[{"award-number":["602012"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.vaccine.2020.09.062","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T18:11:34Z","timestamp":1602007894000},"page":"4903-4913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Protective efficacy of a polyvalent influenza A DNA vaccine against both homologous (H1N1pdm09) and heterologous (H5N1) challenge in the ferret model"],"prefix":"10.1016","volume":"39","author":[{"given":"Kate","family":"Guilfoyle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Major","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Skeldon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanette L.","family":"Tingstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotta","family":"Polacek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ria","family":"Lassauni\u00e9re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0465-9908","authenticated-orcid":false,"given":"Othmar G.","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Fomsgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.09.062_b0005","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.09.062_b0010","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1046\/j.1365-2672.2001.01492.x","article-title":"A history of influenza","volume":"91","author":"Potter","year":"2001","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.vaccine.2020.09.062_b0015","unstructured":"World Health Organization. Pandemic (H1N1) 2009 - update 67 n.d. https:\/\/www.who.int\/csr\/don\/2009_09_25\/en\/ (accessed December 3, 2019)."},{"key":"10.1016\/j.vaccine.2020.09.062_b0020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1600-065X.2010.00980.x","article-title":"DNA vaccines: an historical perspective and view to the future","volume":"239","author":"Liu","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2020.09.062_b0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1750-2659.2010.00177.x","article-title":"Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades","volume":"5","author":"Bragstad","year":"2011","journal-title":"Influenza Other Respi Viruses"},{"key":"10.1016\/j.vaccine.2020.09.062_b0030","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.4161\/hv.25048","article-title":"Antibiotic-free production of a herpes simplex virus 2 DNA vaccine in a high yield cGMP process","volume":"9","author":"Nelson","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.09.062_b0035","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2174\/156652321403140819122538","article-title":"DNA improving vaccine performance through vector design","volume":"14","author":"Williams","year":"2014","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.vaccine.2020.09.062_b0040","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/14760584.2016.1124762","article-title":"Molecular mechanisms for enhanced DNA vaccine immunogenicity","volume":"15","author":"Li","year":"2016","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2020.09.062_b0045","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1080\/21645515.2017.1321183","article-title":"Increased humoral immunity by DNA vaccination using an -tocopherol-based adjuvant","volume":"13","author":"Karlsson","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.09.062_b0050","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.rvsc.2010.04.026","article-title":"Evaluation of the immune response induced by intradermal vaccination by using a needle-less system in comparison with the intramuscular route in conventional pigs","volume":"90","author":"Ferrari","year":"2011","journal-title":"Res Vet Sci"},{"key":"10.1016\/j.vaccine.2020.09.062_b0055","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1128\/CVI.05171-11","article-title":"DNA Vaccination elicits protective immune responses against pandemic and classic swine influenza viruses in pigs","volume":"18","author":"Gorres","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2020.09.062_b0060","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1016\/j.vaccine.2016.05.030","article-title":"A polyvalent influenza DNA vaccine applied by needle-free intradermal delivery induces cross-reactive humoral and cellular immune responses in pigs","volume":"34","author":"Borggren","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.062_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189780","article-title":"Multigenic DNA vaccine induces protective cross-reactive T cell responses against heterologous influenza virus in nonhuman primates","volume":"12","author":"Koday","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.09.062_b0070","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1080\/21645515.2017.1330236","article-title":"Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity","volume":"13","author":"Suschak","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.09.062_b0075","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.vaccine.2009.02.061","article-title":"DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial","volume":"27","author":"Jones","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.062_b0080","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1016\/j.vaccine.2005.08.012","article-title":"Epidermal DNA vaccine for influenza is immunogenic in humans","volume":"24","author":"Drape","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.062_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206838","article-title":"Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140\/GLA vaccines in a phase II randomized factorial trial design","volume":"13","author":"Viegas","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.09.062_b0090","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: ready for prime time?","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.vaccine.2020.09.062_b0095","first-page":"283","article-title":"DNA vaccines: how much have we accomplished in the last 25 years?","volume":"6","author":"Rosa","year":"2015","journal-title":"J Vaccines Vaccin"},{"key":"10.1016\/j.vaccine.2020.09.062_b0100","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(17)33105-7","article-title":"Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials","volume":"391","author":"Gaudinski","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.09.062_b0105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.vetimm.2017.11.007","article-title":"Protective effect of a polyvalent influenza DNA vaccine in pigs","volume":"195","author":"Karlsson","year":"2018","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2020.09.062_b0110","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1080\/21645515.2015.1011987","article-title":"Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans","volume":"11","author":"Borggren","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.09.062_b0115","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/vaccines1030225","article-title":"Vector design for improved DNA vaccine efficacy. Safety and production","volume":"1","author":"Williams","year":"2013","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2020.09.062_b0120","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-1-4939-0410-5_6","article-title":"Development of antibiotic-free selection system for safer DNA vaccination","volume":"1143","author":"Luke","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2020.09.062_b0125","unstructured":"Who. Manual for the laboratory diagnosis and virological surveillance of influenza. World Heal Organ 2011 2011:153."},{"key":"10.1016\/j.vaccine.2020.09.062_b0130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jviromet.2014.09.003","article-title":"An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera","volume":"210","author":"Couzens","year":"2014","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2020.09.062_b0135","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1038\/nprot.2014.180","article-title":"Influenza A virus isolation, culture and identification","volume":"9","author":"Eisfeld","year":"2014","journal-title":"Nat Protoc"},{"key":"10.1016\/j.vaccine.2020.09.062_b0140","doi-asserted-by":"crossref","DOI":"10.1038\/laban1004-50","article-title":"The ferret: an animal model to study influenza virus","volume":"33","author":"Maher","year":"2004","journal-title":"Lab Anim (NY)"},{"key":"10.1016\/j.vaccine.2020.09.062_b0145","article-title":"The ferret model for influenza","volume":"15","author":"Matsuoka","year":"2009","journal-title":"Curr Protoc Microbiol"},{"key":"10.1016\/j.vaccine.2020.09.062_b0150","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1242\/dmm.007823","article-title":"The ferret as a model organism to study influenza A virus infection","volume":"4","author":"Belser","year":"2011","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.vaccine.2020.09.062_b0155","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.virol.2015.03.017","article-title":"Ferret models of viral pathogenesis","volume":"479","author":"Enkirch","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.09.062_b0160","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev-med-120611-145115","article-title":"Toward a universal influenza virus vaccine: prospects and challenges","volume":"64","author":"Pica","year":"2013","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.vaccine.2020.09.062_b0165","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMra1002842","article-title":"CURRENT CONCEPTS influenza vaccines for the future","volume":"363","author":"Lambert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.09.062_b0170","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.vaccine.2013.02.061","article-title":"A polyvalent influenza A DNA vaccine induces heterologous immunity and protects pigs against pandemic A(H1N1)pdm09 virus infection","volume":"31","author":"Bragstad","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.062_b0175","doi-asserted-by":"crossref","first-page":"17736","DOI":"10.1073\/pnas.0807142105","article-title":"Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion","volume":"105","author":"Russell","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2020.09.062_b0180","first-page":"41","article-title":"pandemic H1N1 human influenza virus","volume":"2010","author":"Busquets","year":"2009","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2020.09.062_b0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040524","article-title":"Conserved synthetic peptides from the hemagglutinin of influenza viruses induce broad humoral and T-cell responses in a pig model","volume":"7","author":"Vergara-Alert","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.09.062_b0190","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-019-0463-x","article-title":"Novel correlates of protection against pandemic H1N1 influenza A virus infection","volume":"25","author":"Ng","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2020.09.062_b0195","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1128\/JVI.03030-12","article-title":"Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques","volume":"87","author":"Jegaskanda","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.09.062_b0200","doi-asserted-by":"crossref","DOI":"10.1038\/nm.3350","article-title":"Cellular immune correlates of protection against symptomatic pandemic influenza","author":"Sridhar","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2020.09.062_b0205","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02332-17","article-title":"NAction! how can neuraminidase-based immunity contribute to better influenza virus vaccines?","volume":"9","author":"Krammer","year":"2018","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2020.09.062_b0210","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.4049\/jimmunol.181.6.4168","article-title":"A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus","volume":"181","author":"Carragher","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.09.062_b0215","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1099\/jgv.0.000518","article-title":"Cross-protective potential of anti-nucleoprotein human monoclonal antibodies against lethal influenza A virus infection","volume":"97","author":"Fujimoto","year":"2016","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2020.09.062_b0220","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.4049\/jimmunol.1003057","article-title":"Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus","volume":"186","author":"LaMere","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.09.062_b0225","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0264-410X(96)00268-X","article-title":"Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination","volume":"15","author":"Donnelly","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.062_b0230","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1086\/588431","article-title":"Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A\/Vietnam\/1203\/04 (H5N1) influenza virus","volume":"197","author":"Lalor","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.09.062_b0235","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/S0264-410X(02)00049-X","article-title":"DNA vaccination of ferrets with chimeric influenza A virus hemagglutinin (H3) genes","volume":"20","author":"Ljungberg","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.062_b0240","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1089\/vim.2006.19.147","article-title":"Cellular immunity and lung injury in respiratory virus infection","volume":"19","author":"Bruder","year":"2006","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2020.09.062_b0245","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1099\/0022-1317-83-8-1851","article-title":"Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus","volume":"83","author":"Heinen","year":"2002","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2020.09.062_b0250","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.4049\/jimmunol.1800142","article-title":"Comparison of heterosubtypic protection in ferrets and pigs induced by a single-cycle influenza vaccine","volume":"200","author":"Holzer","year":"2018","journal-title":"J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20312330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20312330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:00:58Z","timestamp":1759402858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20312330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":50,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0264410X20312330"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.09.062","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protective efficacy of a polyvalent influenza A DNA vaccine against both homologous (H1N1pdm09) and heterologous (H5N1) challenge in the ferret model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.09.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}